Darzalex Faspro Gains US FDA AdComm Support For Smoldering Myeloma Claim

The use of J&J’s Darzalex Faspro in high-risk smoldering multiple myeloma could result in overtreatment, but the FDA committee voted in favor of the new claim for delay in development of multiple myeloma.